Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Vertex Pharmaceuticals (VRTX) is trading at $520.94, up 0.89% on the day. Its market value of $132.04B makes it the 117th largest of the 300 companies we follow.
The 52-week range is $384.39 to $560.25. Today's price is about 78% of the way from the low to the high. Holders are ahead 38.3% over twelve months, and up 9.6% across the last three months.
On the chart it holds above both the 50-day ($512.70) and 200-day ($471.12) moving averages; RSI is 50, and the last 30 sessions moved at roughly 26% annualized volatility.
Revenue for the quarter ended Jun 2026 was $3.33B, up 12.5% from a year earlier, with $1.10B of net profit (a 35.0% margin).
Buyers are paying 30.3 times trailing earnings. The median for its industry group is 34.0.
24 analysts follow the stock and the average call is "buy". The mean target, $579.00, sits 11.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Vertex Pharmaceuticals makes cystic fibrosis treatments and is developing pain, kidney and diabetes therapies.
What tends to move it. Its cystic fibrosis sales are a steady base, and the market focuses on the Journavx pain drug and the pipeline.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.6% | Bearish |
| Price vs 50-day average | +1.6% | Bullish |
| Price vs 200-day average | +10.6% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 50.1 | Bullish |
| MACD (12,26,9) | -1.97 | Bearish |
| Bollinger band position | 37% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 79th percentile, 5-year average -19.3x
#2069 of 2975 stocks by PE (1 = cheapest)
Above its usual level · 61st percentile, 5-year average 6.4x
#4541 of 5302 stocks by PB (1 = cheapest)
Above its usual level · 68th percentile, 5-year average 9.8x
#4414 of 5141 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$72.81M (15 inflow days, 5 outflow days).
$520.94 is the latest print for VRTX, a move of +0.89% against yesterday's close of $516.34. Today's low and high so far: $515.30 and $528.89.
Equity value comes to $132.04B at the current price. By that measure it is number 117 of the 300 names in our coverage.
Buyers pay 30.3 times the last twelve months of profit (EPS $15.32).
The year's floor is $384.39 and the ceiling $560.25. Shares are 7.0% away from that ceiling.
Our data shows no dividend paid by Vertex Pharmaceuticals over the trailing twelve months.
Of 24 analysts, 88% say buy, 8% hold and 4% sell. Price targets average $579.00, with the most cautious at $350.00 and the most optimistic at $672.00.
Vertex Pharmaceuticals makes cystic fibrosis treatments and is developing pain, kidney and diabetes therapies.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.